Merit Financial Group LLC Has $405,000 Stake in DexCom, Inc. (NASDAQ:DXCM)

Merit Financial Group LLC increased its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 102.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,933 shares of the medical device company's stock after acquiring an additional 3,000 shares during the quarter. Merit Financial Group LLC's holdings in DexCom were worth $405,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Geode Capital Management LLC grew its holdings in shares of DexCom by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 9,993,698 shares of the medical device company's stock worth $775,256,000 after purchasing an additional 56,094 shares in the last quarter. Norges Bank bought a new position in DexCom in the fourth quarter worth $385,367,000. Northern Trust Corp lifted its position in DexCom by 22.2% in the fourth quarter. Northern Trust Corp now owns 4,146,249 shares of the medical device company's stock worth $322,454,000 after purchasing an additional 753,857 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in DexCom by 3.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,825,206 shares of the medical device company's stock worth $219,716,000 after buying an additional 91,051 shares in the last quarter. Finally, Artisan Partners Limited Partnership increased its holdings in DexCom by 12.2% in the 4th quarter. Artisan Partners Limited Partnership now owns 1,853,565 shares of the medical device company's stock valued at $144,152,000 after buying an additional 201,181 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

DXCM has been the subject of a number of analyst reports. Cfra Research raised shares of DexCom to a "hold" rating in a report on Friday, March 21st. Mizuho began coverage on DexCom in a research note on Thursday, April 10th. They issued an "outperform" rating and a $85.00 price objective on the stock. Wells Fargo & Company restated an "overweight" rating on shares of DexCom in a research report on Saturday, March 8th. The Goldman Sachs Group initiated coverage on DexCom in a research note on Friday, May 30th. They issued a "buy" rating and a $104.00 price target on the stock. Finally, Piper Sandler dropped their price objective on DexCom from $100.00 to $90.00 and set an "overweight" rating for the company in a research note on Friday, May 2nd. Four research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, DexCom has an average rating of "Moderate Buy" and an average target price of $98.32.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Michael Jon Brown sold 10,000 shares of the stock in a transaction dated Friday, May 23rd. The stock was sold at an average price of $84.28, for a total value of $842,800.00. Following the transaction, the executive vice president now owns 95,602 shares of the company's stock, valued at approximately $8,057,336.56. This represents a 9.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Sadie Stern sold 6,184 shares of the company's stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $85.11, for a total value of $526,320.24. Following the completion of the sale, the executive vice president now directly owns 109,621 shares of the company's stock, valued at approximately $9,329,843.31. This trade represents a 5.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 16,536 shares of company stock valued at $1,393,876. 0.32% of the stock is currently owned by insiders.

DexCom Trading Down 1.0%

DXCM traded down $0.86 during mid-day trading on Thursday, reaching $82.13. The stock had a trading volume of 524,162 shares, compared to its average volume of 4,320,186. The stock has a market capitalization of $32.20 billion, a P/E ratio of 57.43, a P/E/G ratio of 2.30 and a beta of 1.46. DexCom, Inc. has a 52 week low of $57.52 and a 52 week high of $118.80. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The firm's fifty day simple moving average is $77.65 and its two-hundred day simple moving average is $79.25.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.01). The firm had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.02 billion. DexCom had a return on equity of 30.14% and a net margin of 14.29%. The business's revenue for the quarter was up 12.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.32 earnings per share. On average, equities analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.